The End of Alzheimer’s - 2nd Edition - ISBN: 9780128121122, 9780128121139

The End of Alzheimer’s

2nd Edition

The Brain and Beyond

Authors: Thomas Lewis Clement Trempe
eBook ISBN: 9780128121139
Paperback ISBN: 9780128121122
Imprint: Academic Press
Published Date: 12th May 2017
Page Count: 482
Tax/VAT will be calculated at check-out Price includes VAT (GST)
30% off
30% off
30% off
30% off
30% off
20% off
20% off
30% off
30% off
30% off
30% off
30% off
20% off
20% off
30% off
30% off
30% off
30% off
30% off
20% off
20% off
57.95
40.56
40.56
40.56
40.56
40.56
46.36
46.36
48.99
34.29
34.29
34.29
34.29
34.29
39.19
39.19
79.95
55.97
55.97
55.97
55.97
55.97
63.96
63.96
Unavailable
Price includes VAT (GST)
× DRM-Free

Easy - Download and start reading immediately. There’s no activation process to access eBooks; all eBooks are fully searchable, and enabled for copying, pasting, and printing.

Flexible - Read on multiple operating systems and devices. Easily read eBooks on smart phones, computers, or any eBook readers, including Kindle.

Open - Buy once, receive and download all available eBook formats, including PDF, EPUB, and Mobi (for Kindle).

Institutional Access

Secure Checkout

Personal information is secured with SSL technology.

Free Shipping

Free global shipping
No minimum order.

Description

The End of Alzheimer’s: The Brain and Beyond, Second Edition is the first comprehensive overview on the molecular basis of Alzheimer’s outside of the brain, merging the most recent findings within the field into a single book. It aims to educate the reader on the many overlooked aspects of Alzheimer’s disease that occur outside the brain.

This book uniquely provides step-by-step, peer-reviewed evidence that the current research model may be misguided and that a new and emerging model is more accurate. It carefully outlines the molecular research in Alzheimer’s outside the brain and argues that a more thorough, whole-body diagnosis will provide better answers about its causes and lead to new treatments.

It is beneficial to researchers who need to be apprised of the emerging science on the causes of Alzheimer’s, and will hopefully redirect many into new avenues of cellular research and discovery.

Key Features

  • Comprehensive literature-based summary of the current state of molecular Alzheimer’s disease research
  • Details the shortcomings of the prevailing model and therapeutics in development
  • Reviews blood-based biomarkers for Alzheimer’s and their link to amyloid- and Tau-independent causes outside the brain
  • Describes the tissues outside the brain impacted by Alzheimer’s and the underlying molecular causes
  • Explains the whole-body risks associated with Alzheimer’s, along with concomitant measures to slow or prevent the disease
  • Provides a protocol to properly research, evaluate, measure, diagnose, and potentially treat Alzheimer’s patients

Readership

Neuroscientists, neurobiologists, neurophysiologists, neurologists, graduate students, and post-doctoral fellows, medical doctors with specialization in infectious diseases, cardiovascular diseases, ophthalmology, optometry, internal medicine, integrative and functional medical practitioners, and doctors of osteopathy

Table of Contents

1. Is it Alzheimer’s?
2. The Amyloid Cascade Hypothesis Chapter includes new information on failed drugs based on the amyloid hypothesis, as well as corroborating evidence that amyloid may be protective.
3. Diagnosis of Alzheimer’s
4. Molecular Causes and Research
Updated chapter
5. Can Medicine Save You? This will include a new section on medical care and outcomes based on The Organisation for Economic Co-operation and Development (OECD). They compare costs on healthcare spending and outcomes. America spends the most, by far, but is near the bottom of the 35 OECD countries on essentially every measure of health. This shows a strong inverse cause/effect between healthcare implementation / spending and health outcomes in a drug-based healthcare system.
6. A New Diagnostic Paradigm – The Molecular Eye Some updates as the eye is gaining traction as a diagnostic modality.
7. Inflammation – Friend or Foe? Minor but important updates: With more experts saying that infection is part of AD causation, the cause of inflammation is becoming clearer.
8. Alzheimer’s Beyond the Brain – Molecular Research in the Body Minor but important updates: There is much new research linking metabolic conditions to AD, and another new finding is the connection between the gut and Alzheimer’s. That too will be included.
9. Does Infection Cause Alzheimer’s? This is updated based on significant new research published in 2016.
10. Alzheimer’s Disease Prevention This has been updated based on infection and the gut becoming more mainstream.
11. Differential Diagnosis toward a Cure for Alzheimer’s

Appendix 1: Signs, symptoms, and stages of Alzheimer’s
Appendix 2: Alzheimer’s Research at the Cellular Level
Appendix 3: Concept of a Medical "Cure"
Appendix 4: Alzheimer’s Disease Statistics
Appendix 5: Eye and Whole Body Diseases

Details

No. of pages:
482
Language:
English
Copyright:
© Academic Press 2017
Published:
Imprint:
Academic Press
eBook ISBN:
9780128121139
Paperback ISBN:
9780128121122

About the Author

Thomas Lewis

Dr. Lewis is an inorganic and physical chemist with degrees from Worcester Polytechnic Institute (WPI) and the Massachusetts Institute of Technology (MIT). In addition to a Ph.D., Dr. Lewis has training from the Harvard School of Public Health in Toxicology, Industrial Hygiene, and a certificate in Industrial Hygiene from the University of Massachusetts. Fundamentally Dr. Lewis is a medical researcher and medical information translator. Much of his knowledge comes for the clinical work of Dr. Clement L. Trempe and Dr. Kilmer McCully. These clinicians are pioneers in systemic chronic diseases, disease detection using ocular biomarkers, germ theory, inflammatory diseases, and micronutrient balance in immune health. He is the founder of the RealHealth companies including RealHealth Clinics. Dr. Lewis is also engaged in developing new small molecule therapeutics for the treatment of diseases of aging, with special focus on Alzheimer’s disease. Dr. Lewis holds patents (pending) on novel approaches to treat cancer and methods and approaches for treating chronic diseases of aging, including Alzheimer’s disease and macular degeneration. In addition, he has patents pending on a new risk calculator for chronic disease which he has trademarked "chronic disease temperature(tm)."

Affiliations and Expertise

RealHealth Clinics, USA

Clement Trempe

Dr. Trempe received his MD degree from Ottawa Medical School, Canada. He furthered his studies at Harvard’s Schepens Eye Research Institute (SERI) and Massachusetts Eye and Ear Infirmary, Boston. He has been on staff at Harvard Medical School teaching hospitals since the 1970s. Dr. Trempe didn’t set out to solve the Alzheimer’s conundrum, he instead set out to treat eye diseases in a different way: treat the causes of the sick body and the health of the eye will also improve. When Dr. Trempe started diagnosing and treating his “eye” patients for systemic diseases, their eyes got better and stayed much better compared to people who were treated as if their eyes existed in isolation from the rest of the body. This multidisciplinary approach resulted in many patients with serious disease beyond the eye reporting that their other conditions improved upon Dr. Trempe’s “eye” (whole body) treatments. One of those conditions that improved was Alzheimer’s disease. His medical career at Harvard Medical School has spanned five decades. He is the author of hundreds of medical/scientific papers, two pending patents, and two books.

Affiliations and Expertise

Clinical Assistant in Ophthalmology, Harvard Medical School, Boston, MA, USA; Assistant in Ophthalmology, Massachusetts Eye and Ear Infirmary, Boston, MA, USA